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List of abbreviations
3D-Bioinfo: name of the ELIXIR Community of structural 
bioinformatics
BioExcel: Center of excellence for biomolecular research
Biomedinfra: authenticaton and authorisation infrastructure 
(ELIXIR AAI) of ELIXIR Finland
CAMEO: Continuous Automated Model Evaluation
CAPRI: community-wide experiment on the comparative 
evaluation of protein-protein docking for structure prediction
CASP: critical Assessment of protein structure prediction
ChEMBL: a manually curated database of bioactive molecules 
with drug-like properties
COOT: crystallographic object-oriented toolkit, a graphics for 
refinement of experimental biomolecular structures
COST: (European) cooperation in science and technology
EMDB: Electron microscopy data bank
ELIXIR: intergovernmental organisation that brings together 
life science resources from across Europe
EM, cryo-EM: electron microscopy, cryo-electron microscopy
EOSC-Hub: European Open Science Cloud
EU-OPENSCREEN: integrates high-capacity screening platforms 
throughout Europe
FAIR: data which meet principles of findability, accessibility, 
interoperability, and reusability
FARFAR: fragment assembly of RNA with full-atom refinement
FARNA,: fragment assembly of RNA




MMB: MacroMolecularBuilder. A program suite for macromolecu-
lar modelling
MX macromolecular X-ray crystallography
NMR: nuclear magnetic resonance, a spectroscopic method
OpenEBench: infra-structure designed to establish a continuous 
automated benchmarking system for bioinformatics
PDB: Protein data bank
PDBe-KB: Protein data bank in Europe - knowledge base
PDB-Redo: procedure to optimise crystallographic structure 
models
Phenix: software suite for the automated determination of 
molecular structures
PHYRE: automatic fold recognition server for predicting the 
structure and/or function of the protein sequence
Proteopedia: wiki and 3D encyclopedia of proteins and other 
biomolecules
Pubchem: database of chemical molecules and their activities
Refmac: program for refinement of experimental structures of 
biomolecules
RNA Puzzles: collective experiment for blind RNA structure 
prediction
SAXS: small angle X-ray scattering
SBDD: structure-based drug design
Swiss-model: structural bioinformatics web-server dedicated to 
homology modelling of 3D protein structures
TeSS portal: ELIXIR’s training portal
UniProt: Universal protein esource, a comprehensive resource for 
protein sequence and annotation data
Web-Beagle: web server for the alignment of RNA secondary 
structures
Major European contributions in structural 
bioinformatics
Structural bioinformatics is a well-established scientific activ-
ity, which started in the 1970s following the establishment of 
the Protein Data Bank1 which provides open access to macro-
molecular structure models. Figure 1 illustrates major themes in 
structural bioinformatics. Structure data can give deeper insights 
into the mechanism of proteins, the functions of biomolecules 
(proteins, nucleic acids, carbohydrates, lipids, etc.) and their 
interactions with each other and with chemical modulators of 
their functions (inhibitors, activators, co-factors, etc.). This 
enables the design of new experiments to study the function of 
macromolecules as well as rational design of proteins and drugs, 
to modify their function and properties.
Structure models are experimentally determined by macromo-
lecular X-ray crystallography (MX) and small angle X-ray scat-
tering (SAXS), nuclear magnetic resonance spectroscopy (NMR), 
or cryo-electron microscopy (EM). The technological develop-
ments in MX in the previous decade, largely catalysed by the 
structural genomics initiatives and the on-going revolution in 
the field of cryo-EM, are expanding the volume of structural 
data both quantitatively and qualitatively (see Figure 2). 
European structural bioinformatics groups have played a crucial 
role in the development of methods to validate this data2,3 
and the world-wide adoption of these tools by the structural 
biology community. They have also initiated collaborations and 
joint activities between structural bioinformaticians and struc-
tural biologists, expanding recently to meet the need to develop 
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Figure 1. Schematic illustrating major themes in structural bioinformatics. Top row – protein structure validation, protein structure 
comparison and classification, protein ligand interactions, nucleic acid structures, protein-protein interactions and complexes; middle row 
– protein structure prediction, prediction of protein interactions, protein structure dynamics; bottom row – integration of protein structure 
and sequence to predict functional sites and effects of genetic variations, exploiting protein structure annotations for comparative genome 
studies.
tools and validation protocols for structures determined 
using new techniques such as EM (cryoEM, microED) and 
Integrative/hybrid methods.
European bioinformatics groups have also been at the forefront 
of efforts to compare protein structures and characterise their 
features in order to understand the underlying principles of 
protein structure and function4 and thereby promote both funda-
mental and translational research. For example, characterisation 
of protein binding pockets provided vital information for 
rational drug design. Europe also pioneered the establish-
ment of comprehensive structure-based protein classifications5,6 
giving structural insights into protein evolution and European 
structure-based tools have facilitated enzyme reaction mechanism 
studies by chemists and biochemists.
Another major European activity, the prediction of protein struc-
tures from amino acid sequences, started in the late 1980s. 
European groups were amongst the first to predict protein 
secondary and tertiary structure for soluble and membrane associ-
ated proteins. Additionally, some of the most critical contributions 
to building protein 3D models from structural templates of 
homologous proteins, happened in Europe in the 1990s7,8, 
together with the development of methods for assessing model 
quality. European bioinformatic groups have also provided 
key solutions for the hardest task of de novo prediction of 
protein spatial structures9. Furthermore, European groups have 
made seminal contributions to the development of methods 
for modelling the 3D structure of protein complexes10, a very 
difficult problem, which is centre stage for today’s molecular 
biology. These activities have been further expanded in the field 
of multi-scale modelling where a wide variety of experimen-
tal and bioinformatics data are integrated into the modelling 
process. Importantly European groups have made major con-
tributions to initiatives assessing the performance of structure 
prediction and protein docking methods (see reviews 11–13).
European research groups contributed significantly to the 
field of RNA bioinformatics, setting standards in RNA struc-
ture predictions, modeling, and data format14,15. In particular, 
the RNA-Puzzles experiment for evaluation of RNA structure 
prediction methods, and a series of associated workshops 
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Figure 2. (a) Total number of PDB entries and number of entries for each major experimental type. (b) Number of nuclear magnetic resonance 
(NMR) and electron microscopy (EM) entries deposited per year. (c) Number of new entries deposited each year and number of new proteins 
(UniProt accession) added per year.
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have been introduced in Europe, attracting the top groups 
world-wide16,17,18.
Protein function is strongly related to molecular recognition 
of small molecules such as substrates, inhibitors, or signal-
ling compounds and many European groups have been active in 
this area over the last 50 years19,20,21 and remain major players in 
the field. Europe also has an exemplary track record in devel-
oping molecular dynamics (MD) simulation techniques and 
applying them to investigate dynamic properties of protein 
systems, functionally important conformational transitions 
in proteins, as well as folding and unfolding reactions22,23,24, 
providing crucial insight into dynamics aspects that are 
notoriously difficult to capture by experimental approaches.
Protein structural data and functional residue annotations 
also inform protein engineering, another important activ-
ity with significant European representation. For instance, the 
discovery of canonical conformations in antibody variable 
domains25 spurred the development of the first methods for 
accurate structure prediction in antibodies26. Other biocompu-
tational methods have been important for enzyme engineering. 
Such contributions by European bioinformaticians have trans-
formed the face of protein engineering and were the basis for 
establishing major biotechnological companies for developing 
new research and clinical tools.
Major challenges that 3D-Bioinfo will help to address
Improvements in structure prediction opens up huge possibili-
ties including understanding the effects of disease causing muta-
tions, and provides an essential platform for almost all future 
translational efforts including developing novel drugs. Fur-
thermore, international initiatives (i.e. CASP27, CAMEO28 and 
CAPRI29,30 for assessment of the prediction of protein struc-
tures and complexes have driven the field by independently 
validating methods and highlighting innovations that increase 
performance. However, many challenges still exist. It 
remains computationally expensive to build 3D models on a 
proteome-wide scale. Furthermore, prediction methods are still 
error prone. It is therefore important to increase coverage and 
confidence measures by consolidating results from multiple 
methods. ELIXIR is already supporting some Europe-wide 
collaborative initiatives. For example, a recent implementation 
study links several major structure prediction and annotation 
resources (SWISS-MODEL31, PHYRE32, GenTHREADER33, 
Fugue34, SUPERFAMILY35, CATH-Gene3D36) with ELIXIR 
Core Resources, PDBe37 and InterPro38 to increase the coverage 
and reliability of predicted protein structure data (see Figure 3).
Structural bioinformatics tools link sequence and structure 
data to predict protein functional sites. As for protein struc-
ture prediction, integration of data on sites predicted by dif-
ferent methods will increase both coverage and accuracy. In 
this context, new initiatives like the PDBe Knowledgebase 
(PDBe-KB) are integrating data from multiple European 
groups allowing easy access, development of meta-predictors 
and common benchmarking to improve accuracy. Since some 
disease-associated genetic variations result in modifications 
of protein residues in or near functional sites, these initiatives 
provide a natural link with the ELIXIR Human Rare Disease 
Community.
Recent and future technological challenges of structural biol-
ogy such as EM, serial crystallography, fragment screening, 
bio-SAXS, time-resolved structural methods, and techniques 
of integrated biology in general, are important areas that can be 
addressed by structural (3D) bioinformatics, albeit always in 
close collaboration with structural biology research groups. 
Optimal data formats, FAIRness39 of the data, interoper-
ability of the data and software tools are serious issues that 
Figure 3. The coverage of protein sequences from selected model organisms with structural annotations provided by the Genome3D 
resource.
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require close collaboration between structural biologists and 
bioinformaticians.
With regard to prediction of protein-ligand interactions, 
protein/drug design, and modelling of dynamic properties of 
proteins and their interactions, much work remains to be done 
in benchmarking of methods and better integration of methods 
and data. 3D-Bioinfo will endeavour to facilitate collaborations 
and new initiatives in these areas.
Goals of 3D-BioInfo
The major goals of 3D-Bioinfo will be to increase interoper-
ability between resources by developing and promoting data 
standards, integrating data where appropriate and develop-
ing robust benchmarking strategies for prediction algorithms 
(e.g. protein structures, complexes, ligand/drug docking). We 
will also develop better visualization frameworks for protein 
and nucleic acid structures and work closely with the struc-
tural biology community and initiatives such as Instruct-ERIC to 
develop improved validation metrics for nucleic acid structures, 
an important area, which is currently underdeveloped.
The 3D-Bioinfo major goals can be summarized as follows:
•    Promote and develop data standards to drive data integration
•    Plan the long-term sustainability for key computational tools 
and data resources
•    Drive the integration of resources and tools for analysis of 
structural data
•    Develop robust standard methods for benchmarking and 
validating prediction tools
•    Facilitate the access of tools requiring high compute power to 
the appropriate facilities
•    Improve integration of structural data with other quantitative 
biological data
•    Pool and expand the available training and outreach material 
in structural bioinformatics.
Links between 3D-Bioinfo and the wider European 
research environment
The structural bioinformatics community forms an indis-
pensable interface between producers of structural data and 
their users. There are already several ELIXIR endorsed node 
resources/servers (SWISS-MODEL31, Phyre32) and Core Data 
Resources (PDBe37, CATH36) in 3D-Bioinfo.
European groups participating in 3D-Bioinfo have been involved 
in European networks providing derived structural data and 
analysis tools to biologists (e.g. InteGr8, IMPACT, Biosapiens, 
Instruct-ERIC, BioExcel, Biomedinfra, EU-OPENSCREEN, 
EOSC-Hub) and COST Actions (e.g. CA15135 - Multi-target 
paradigm for innovative ligand identification in the drug 
discovery process; CM1306 - Understanding Movement and 
Mechanism in Molecular Machines, COST Action BM1405 
(CA17139 EUTOPIA (EUropean TOPology Interdiscipli-
nary Action), WP3 Entangled and Self-entangled Proteins). 
Other international collaborations include the Protein Struc-
ture Initiative (PSI) for structural genomics. A significant 
fraction of the tools/resources provided by ELIXIR nodes 
relates to structural bioinformatics and the combined resources 
receive hundreds of thousands of web-accesses/month from 
the wider global research community.
3D-Bioinfo Executive and Steering Committees
The 3D-Bioinfo Community includes leading figures in the 
field of structural bioinformatics across Europe. It was initiated 
in March 2018 with the formation of a Steering Committee 
and an Executive Committee comprising representatives from 
16 ELIXIR nodes. These members actively sought further 
participants from within their nodes, covering a wide spec-
trum of skills and needs (see European groups participating in 
3D-Bioinfo). They are responsible for the development and 
sustainable operation of complex tools ranging from databases 
to infrastructures promoting interoperability between multiple 
areas of research that rely on the reusability of structural data 
provided by the structural biology community (e.g. as represented 
by Instruct-ERIC).
Description of the launch meeting
3D-BioInfo was launched at a meeting in Basel, September 
2018, with 70 participants from 15 European countries provid-
ing their input. In addition to presentations from committee 
members on the proposed 3D-Bioinfo Activities, representatives 
of the five ELIXIR platforms on data, tools, interoperability, 
compute and training, described their activities. John Hancock 
also gave a presentation as Coordinator of ELIXIR Commu-
nities and representative of the ELIXIR hub. Additionally, 19 
‘flash talks’ were given by European research groups inter-
ested in contributing to one or more of the proposed 3D-Bioinfo 
activities and/or to joint activities with the ELIXIR platforms. 
Organisers of related ELIXIR communities (proteomics, intrin-
sically disordered proteins and human copy number variation) 
gave presentations indicating possible areas of future collabo-
ration. There were also oral contributions from representatives 
of other European ESFRI initiatives like Instruct-ERIC and 
BioExcel, again highlighting synergies and possible collabora-
tions. Posters from many research groups, keen to participate in 
3D-Bioinfo, were presented at the meeting highlighting 
their possible contributions and an interactive session was 
held allowing participants to discuss the proposed Activities 
and suggest future Activities. Participants also discussed ideas for 
interaction with the ELIXIR platforms.
Activities and action plans prioritized by 3D-Bioinfo
Following their formation in March 2018, the 3D-Bioinfo 
Executive and Steering Committees held regular conference 
calls to determine the highest priority areas, which would become 
the main Activities to be first undertaken by the community. 
These 3D-BioInfo Activities, outlined below, were further 
discussed and refined at the launch meeting, and involve 
multiple participating groups across the nodes.
Structural Bioinformatics is well established, as the field began 
more than 40 years ago following the establishment of the 
protein structure databank in the 1970s, so most of these 
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Activities represent mature areas of research, some of which 
had already received sustained node funding to develop their 
tools and resources. Each Activity will have the major goals, 
listed above, as the core of their mission. They are being 
coordinated via regular conference calls and are each evolv-
ing specific tasks. Below we detail, the specific thematic 
aims of each Activity and highlight the planned interactions 
with the ELIXIR platforms.
Activity I: Infrastructure for FAIR structural and functional 
annotations
Coordinator: Sameer Velankar. The Protein Data Bank (PDB) 
and the Electron Microscopy Data Bank (EMDB) both follow 
the FAIR principles, thus enabling many niche data resources 
to derive added value annotations from the archived struc-
tural data, such as structure domain classifications, information 
on ligand- and macromolecule binding sites and effects of 
mutations on structure and function. However, a lack of 
coordination between these specialist data resources has pre-
vented the creation of data standards and uniform data access 
mechanisms, consequently reducing the impact of these 
valuable data.
The proposed Activity will address these omissions by fur-
ther developing the PDBe Knowledge Base (PDBe-KB) – a 
community-driven data resource for structural and functional 
annotations that places structural data in its biological context. 
PDBe-KB increases the visibility and interoperability of niche 
data resources by collating minimally required common struc-
ture-based annotation data in a standardized data exchange 
format and by enabling comparisons between specific types of 
annotations obtained from different software tools.
The initial focus of this Activity will include three major 
goals: i) continue to expand the scope of integrating known 
and predicted functional site annotations with PDBe-KB; 
ii) integration of annotations concerning the impacts of 
disease-associated variants on structure and function in 
PDBe-KB; and iii) integration of predicted protein structure 
data via existing model archives by establishing a federated 
infrastructure for access (3D-Beacons).
Identifying additional predicted or manually curated annota-
tions that could further enrich the integrated data of PDBe-KB: 
The lack of data standards and fragmented nature of specialist 
data resources is a barrier to the FAIR principle. We will bring 
together the community experts to define data standards for 
different types of annotations and integration of these anno-
tations using a community-driven data exchange format will 
facilitate finding, accessing and reusing sparse annotations in an 
interoperable manner. Activity I will ensure that PDBe-KB will 
be an effective platform for the collaborating partners to share 
and compare their value-added, structure-derived annotations. 
Furthermore, we will continue to identify gaps in cover-
age of the various types of annotations in PDBe-KB and bring 
together community experts to fill in those gaps. The work-
shops will also facilitate the development and testing of new 
methods by providing valuable, standardized benchmarking 
data sets.
Integration of annotations related to the impacts of disease-
associated variants on structure and function: By bringing 
together developers of specialist data resources and scientific 
software tools that can provide information on the effects of 
amino-acid variation on structure and function, we will establish 
data standards to represent these data. The data standards will 
support integration of these annotations in PDBe-KB with 
particular emphasis on the effect of disease-related muta-
tions on conformational stability. Compiling and integrating 
these annotations will be highly beneficial when investigating 
naturally occurring variations, and when used together with 
all the other types of integrated annotations it may facilitate 
development of better tools ultimately benefiting the wider 
biomedical research community.
Integrating predicted protein structure models (3D-Bea-
cons): Taking advantage of the highly interconnected 
data of PDBe-KB will allow the transfer of valuable annota-
tions to structural models based on sequence- or structural 
similarity when experimentally determined structural data is 
unavailable. Development of 3D-Beacons infrastructure by incor-
porating structural models from existing European archives 
(e.g. SWISS-MODEL31, Genome3D40) and other international 
resources (e.g. MODBASE41 and Gremlin42) will facilitate 
an increase in the coverage of structure data in the sequence 
space. The PDBe-KB data alongside the predicted structure 
models will potentially allow the scientific community to gain 
valuable insights regarding the biological context.
The focused activities will take advantage of the exist-
ing PDBe-KB infrastructure, and will include developing 
community-driven data standards and a uniform data access 
mechanism in addition to novel, portable and distributed 
web-based visualisation components. Activity I will build 
on existing collaborations involving five ELIXIR nodes 
(UK, Italy, Spain, Czech Republic, Belgium).
Activity II: Open resources for sharing, integrating and 
benchmarking software tools for modelling the proteome in 
3D
Coordinator: Shoshana Wodak. Activity II is about empower-
ing the scientific community to extend the current information 
on protein 3D structures, protein interactions and assemblies, 
and extract knowledge from this information by using 
computational and bioinformatics methods, and integrating bio-
logical data from different sources. Its initial focus will be on 
software tools and benchmark datasets for modeling the 3D 
structures and conformational flexibility of proteins and protein 
assemblies, and on community-wide benchmarking activities 
that advance the field. This focus will subsequently be broad-
ened to include other areas where 3D modelling of proteins and 
their interactions is most impactful. The following specific aims 
will be pursued.
Extend the content of OpenEBench by adding a knowledge 
base integrating software tools for modeling the 3D struc-
ture of proteins, protein complexes and assemblies. A variety 
of software tools are available for modeling protein structures 
and protein complexes by exploiting available protein sequence 
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data and information on known structures in the Protein Data 
Bank (PDB). Exploiting these data successfully involves inte-
grating the appropriate set of tools for the problem at hand. 
The Community will tap into OpenEBench a knowledge portal 
fostering benchmarking in the life sciences domain and an impor-
tant component of the ELIXIR Tools Platform, with exemplary 
datasets of CAMEO and CAPRI already present. The extension 
will include workflows and guidelines to software tools 
and servers for modeling protein structures and complexes, 
based on known structures (templates) in the PDB. More 
specifically tools for template-based modeling of protein 
assemblies, and for Integration of template-based modeling of 
individual subunits, with protein-protein and protein-peptide 
docking servers developed by members of the CAPRI com-
munity. For a more in-depth understanding of the resources 
please refer to the CAPRI and CAMEO websites. 3D-Bioinfo 
will build on these efforts and take them to the next level.
Develop a set of standard freely available tools for evaluating 
the quality of 3D models of proteins and protein complexes. 
Evaluating the quality and accuracy of 3D models of proteins 
and protein complexes plays a crucial role in evaluating the 
performance of molecular modeling methods, and helping meth-
ods developers to optimize their procedures. Furthermore, to 
effectively compare the performance across methods, agreed 
upon standard quality measures and evaluation protocols are 
necessary, as implemented for single protein models by 
CAMEO modeling (3D), the CAMEO Quality Estimation (QE) 
category and for protein – protein complexes by the CAPRI 
community. Major goals will include:
1) Full automation of the CAPRI quality assessment pro-
cedures for models of protein-protein and protein-peptide 
complexes, and larger assemblies and making them widely 
accessible online and for download,
2) Integration of the CAPRI and CAMEO model quality 
assessment tools,
3) Making the integrated tools available as open software 
through a community repository (e.g. on GitHub, building on 
the GitHub established by the CAPRI community).
Develop a one-stop-shop of benchmark datasets for testing 
and evaluating methods for generating scoring, and ranking 
models of protein complexes. The availability of appropri-
ate benchmark datasets has been crucial for the development of 
protein modeling procedures at all levels. Protein docking bench-
marks, which assemble high resolution 3D structures of selected 
sets of known protein complexes and their components43,44,45 
as well as their experimentally measured affinities46,47, have 
been widely used for benchmarking methods for protein-protein 
docking, and for predicting and scoring protein interaction 
interfaces. The OpenEBench project within ELIXIR-EXCEL-
ERATE (OpenEBench.bsc.es48) has established a transparent 
data model that allows not only the sharing of benchmarking 
datasets, but also analyzing and comparing the performance 
of different prediction algorithms on these datasets.
OpenEBench will thus foster a collection of benchmark 
datasets relevant to the field of modeling the 3D structure of 
monomeric, homo-oligomeric and heteromeric protein com-
plexes, extending to proteins - peptide and protein - nucleic 
acid interactions. It will include: 1) protein docking and affinity 
benchmark datasets developed by members of the CAPRI com-
munity, 2) datasets comprising all the predicted models of 
protein assemblies submitted to CAPRI and CASP blind pre-
diction challenges, following the examples of the Score-Set49 
derived from predicted models submitted to CAPRI, 3) a dynamic 
benchmark for protein complexes beyond binary interactions, 
considering different difficulty levels (See DynBench3D;50). 
In addition a mechanism will be developed for users to contrib-
ute datasets51, following well-defined community-approved 
standards such as the mmCIF based modeling extension devel-
oped in collaboration with the RCSB within the macromolecular 
ModelArchive.org project.
Develop the infrastructure to manage the CAPRI challenge, in 
coordination with CAMEO. For CAPRI: Develop automated 
registration and submission procedures (including automated 
validation of compliance with standard format), as well as 
tools for accessing and navigating target information, predicted 
models and prediction results on the CAPRI website. Work 
on these tasks is currently underway at CAPRI-EBI, but 
further support is needed to complete it. For CAMEO: CAMEO 
is currently adding a new category for heteromeric complex 
modeling. We propose a close collaboration with CAPRI 
concerning the prediction and scoring applied during fully 
automated evaluations.
Develop a knowledge portal to user-friendly bioinformat-
ics and computational tools for modeling conformational 
flexibility of proteins. Adequate modeling of conformational 
changes is currently a major bottleneck in protein assem-
bly modeling. To foster progress an important first step would 
be to develop a knowledge portal offering the modeling com-
munity at large, workflows and guidelines to various avail-
able computational and bioinformatics tools for modeling 
conformational flexibility. We will use the bio.tools registry 
established by the ELIXIR Tools Platform as infrastructure for 
this. bio.tools has tags, one of which is structure prediction, but it 
should be possible to add more customized tags. With such tools 
playing an important role in modeling intrinsically unstruc-
tured proteins, collaborations with the ELIXIR Community 
on protein intrinsic disorder on topics of common interest 
will be undertaken.
Activity III: Protein-ligand interactions
Coordinator: Vincent Zoete. The biological activity of biomac-
romolecules is often linked to the three-dimensional recognition 
and binding of small molecules such as substrates, activa-
tors or inhibitors. Indeed, a large fraction of drugs are ligands 
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targeting macromolecules like enzymes, receptors, transport-
ers or ion channels. Consequently, important efforts have been 
dedicated to develop computer-aided drug design (CADD) 
and notably structure-based drug design (SBDD) approaches 
over the last decades, contributing significantly to the design of 
small molecules of therapeutic interest.
The field of drug discovery and development will face sev-
eral challenges in the future. The on-going needs in medicinal 
chemistry prompts a dramatic demand for new molecular 
entities and the exploitation of chemical spaces that are yet 
unexplored. Despite important progress over the last few 
decades, toxicity issues remain a problem for small com-
pounds. This has to be addressed through increased specificity, 
but also via a better characterization of the possible targets and 
the anticipation of multiple off-target effects. Toxicogenomics, 
pharmacogenomics, and phenotypic screening data should be 
collected, organized and disseminated to get a clearer 
overview of biomacromolecule-ligand interactions, and to 
ultimately predict in silico the poly-pharmacology of the 
compounds. New target classes are also emerging, beyond the 
usual well-defined binding pockets, including among others the 
interaction of proteins with other proteins, nucleic acids, lip-
ids or sugars. These additions in the target classes are mirrored 
by the use of new classes of ligands, including peptides and 
macrocyclic compounds. These new types of target-ligand 
interactions will foster the development of novel in silico 
approaches, which will require new algorithms and thorough 
evaluations of their descriptive and predictive capacities.
Among other in silico technologies, structure based drug 
design (SBDD) methods remain in great need of comprehensive 
evaluations of their performance and domain of applicability. 
In particular, there is a need for improved docking and 
scoring methods. Although protein-ligand complexes can be 
predicted for small ligands and almost rigid proteins, large, 
flexible molecules like peptides or macrocycles and proteins 
with flexible binding regions are still very difficult to han-
dle. The reliable prediction of the binding free energy of a 
protein-ligand complex also remains a major challenge. Bet-
ter methods making use of precise chemical models, modern 
optimization techniques and innovative scoring approaches are 
still much needed but must be accompanied by comprehensive 
and rigorous evaluations of their performance and domain of 
applicability. This should go hand in hand with the creation of 
processing pipelines for the proper use of structural data, and of 
standardizing tools for IO.
The efficiency of SBDD tools often depends on molecular/
physicochemical properties such as the charge, polarity or size 
of the protein binding site and ligand, as well as on the tar-
get class of the biomacromolecule or the chemical class of the 
ligand. To address this, benchmark sets should clearly list 
and quantify these different properties for each complex with 
suitable descriptors, transparent for the user community. For 
Activity III, we plan the following goals:
Creation of benchmark datasets to assess structure-based 
drug design tools. Benchmarking studies performed so far, 
including those carried out in the CSAR52 or D3R Grand 
Challenge53 which focus on compound series consistently 
measured within one lab/institute - rely on datasets of limited 
size and diversity, precluding large-scale, FAIR comparisons 
of their performance, especially as a function of ligand and 
binding site properties. Activity III will therefore involve:
1) Building benchmark datasets, extracted from the PDB and 
curated, for assessing SBDD tools on a large-scale, under 
well-defined FAIR conditions, thereby complementing efforts 
such as the D3R grand challenges. A particular effort will 
be devoted to collecting complexes involving peptides and 
macromolecules.
2) Quantifying different properties (e.g. charge, polarity, 
size, flexibility of the binding site and ligand etc.) for each 
entry in the benchmark, to enable evaluation of SBDD tools 
as a function of these properties.
3) Developing links to other databases and standardizing the 
retrieved data to complement the information provided for 
each protein-ligand complex in the benchmark sets; nota-
bly, collecting information on ligands in collaboration with 
PDBe-KB, and associating complexes with reliable binding 
affinity data using databases like ChEMBL54 and Pubchem55.
4) Adding information on the non-bioactive conformations of 
ligands to standardize the comparison of docking calculations 
starting from such geometries.
5) Adding information on experimentally determined non-active 
compounds (taken e.g. from ChEMBL54) to be used as 
negative examples for testing virtual screening procedures.
Dissemination and promotion of the benchmark datasets 
and results. Benchmark datasets will be made publicly 
available by following Open Access and FAIR principles via 
a collaboration with the OpenEBench project within ELIXIR 
EXCELERATE. The latter will also allow the sharing of 
benchmarking results, and comparing the performance of 
different prediction algorithms under FAIR conditions. Pre-
ferred standardized benchmark workflows and protocols will 
be published, to guarantee an objective comparison of different 
tools. Researchers will be encouraged to evaluate their pre-
ferred sets of SBDD approaches using the above-mentioned 
standardized benchmarking workflows and protocols, and to 
report their results. We will collect the latter and provide them 
to the community. This activity will be of major value to Pharma 
and Biotech researchers, who acknowledge the importance of 
standard benchmarking protocols.
Biomacromolecule-ligand interactions for every scien-
tist, educational aspects. Despite significant interest in using 
modelling approaches among life scientists, the use of 
biomacromolecules structures in molecular design largely 
remains a domain for experts. However, complex data prepa-
ration and association could be largely automated resulting 
in easier-to-use software and substantially lowering the usage 
barrier for life scientists. By encouraging the development of 
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tutorials guiding the application of modelling and the inter-
pretation of the achieved results, we will endeavour to open 
the world of structure-based modelling to the broader life 
science community.
Activity IV: Tools to describe, analyse, annotate, and 
predict nucleic acid structures
Coordinator: Bohdan Schneider. The ultimate goal and vision 
of Activity IV is to encourage development and use of software 
tools to describe, analyse, annotate, and predict nucleic acid 
(NA) structures. The availability and sophistication of tools 
dealing with various hierarchies of the nucleic acid structure 
lag behind the tools used to explore protein structures and 
this situation must be remedied. In particular, standards are 
needed for initial model building and refinement of nucleic acid 
molecular structures. This task has become urgent as new tech-
niques, including, but not limited to cryo-EM, are generating 
experimental data on 3D structures containing RNA and DNA 
molecules, such as ribosomes, spliceosomes, polymerase assem-
blies, and histone complexes, faster than ever before. The 
modelling of large nucleic acid molecules into low-resolution 
electron densities is particularly challenging. The RNA structural 
bioinformatics community has provided prototype tools, with 
which to model RNA and RNA-protein complexes based on 
experimental data, but these tools are currently not compatible 
with community-wide standards describing RNA and DNA 
conformational space and geometry at the local (nucleotide or 
dinucleotide) levels.
Therefore, efforts need to be directed towards formulating com-
munity-accepted benchmarks that integrate the different levels 
of nucleic acid structure descriptions, and more generally 
to improving software tools that describe, analyse, annotate, and 
model nucleic acid structures. To enable these developments, 
Activity IV will focus on the following specific goals:
1) Cataloguing software tools for building nucleic acid mod-
els based on their sequences alone as well as for modelling 
their 3D structures using experimental data, and facilitate 
integration of these tools.
2) Coordinating the unification of the existing NA geometry 
standards and formulate specifications for missing standards.
3) Developing benchmarks dataset for evaluating the quality 
of predicted or experimentally determined NA structures.
To limit the redundancy and increase the synergy between the 
methods, databases, web services, and other tools, we plan 
to continuously update the catalogue of software tools devel-
oped by the RNA tools and software consortium, extend these 
tools to DNA structures and enable integration of emerging 
tools. These efforts will build on existing ontologies while 
preserving consistency with new extensions.
This integration effort will require a significant level of 
interoperability between data exchange protocols and soft-
ware, which will be implemented following FAIR principles. 
Dealing with software to solve, model, and refine NA 
structures based on the experimental data will require a close 
collaboration with experimentalists. Hence joining forces with 
Instruct-ERIC will be essential, for reaching all the stated 
goals, including the development of benchmarking tools and 
standards.
We list a few examples of steps, which could assist useful 
integration of the existing tools:
1) Adding links from existing servers to other tools, espe-
cially those linking 2D and 3D structure prediction. The RNA 
Tools and Software Consortium have already recapitulated 
methods for RNA secondary structure prediction and to some 
extent RNA 3D tools. The RNA Puzzles community of 
RNA structural bioinformaticians16,17,18 has developed a set 
of tools for linking 2D and 3D structures, software for RNA 
3D structure model evaluation also exists, e.g. RASP56 or 
MacroMoleculeBuilder, MMB57.
2) Unifying the libraries of RNA/DNA dinucleotide frag-
ments based on the analysis of experimental structures58,59 
and trinucleotide fragments60. Ultimately, the community 
should reach a consensus on what is the meaning of 
“preferred”, “allowed” and “wrong” conformers in analogy 
with the use of these terms in the Ramachandran plot.
3) Integrating and benchmarking methods dealing with 
RNA structures, e.g. SimRNA61, RNAComposer62 MMB57, 
FARNA/FARFAR63, Web-Beagle64.
4) Strengthening the collaboration with developers of the main 
experimental nucleic acid structure determination software 
tools (e.g. REFMAC65, COOT66, Phenix67, PDB-REDO68) to 
encourage consistent handling of NAs.
The goals of Activity IV are quite ambitious, and their imple-
mentation will require close and friendly collaboration of 
all research teams willing to participate; including the teams 
involved in this Activity, and other teams active in the field. The 
teams not involved in Activity IV will be encouraged to join. 
Successful completion of the stated goals will also depend on 
the close collaboration of scientists grouped under other infra-
structure projects in Europe and beyond. New tools, stand-
ards and benchmarks developed for NA validation will be 
communicated to the experimental structural biology commu-
nity, mainly Instruct-ERIC but also EuroBioImaging, to ensure 
consistency across the different research communities.
As a part of the 3D-Bioinfo Community, we plan to hold regu-
lar meetings and workshops and web conferences, to infor-
mally discuss progress and help identify problems that can 
be addressed collectively. Unlike other 3D-Bioinfo Activities, 
Activity IV involves a relatively new community that is less 
well established and will require organising workshops to 
encourage collaboration and to enable updating of tool 
catalogues and ontologies. As with the other 3D-Bioinfo 
Activities, we will coordinate organisation of the workshops 
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with the ELIXIR’s training portal TeSS where appropriate. 
The first workshop of the Activity IV is going to take place 
in May 2020.
Future 3D-Bioinfo activities
The above mentioned themes will not only form the initial focus 
for 3D-Bioinfo but the steering committee will actively moni-
tor the emergence of new technologies and/or new research 
fields relevant for bioinformatics approaches, which then 
can be fostered further as new activities. For example, in the 
field of protein design the overarching aim is to enable com-
pletely rational design of proteins with customized biological 
functions e.g. novel biocatalysts for Green Chemistry to meet 
sustainability and environmental challenges. In order to foster 
new developments focused courses/workshops will be organ-
ised on such topics. For example, a course or workshop on 
using biocomputing to understand and engineer biocatalysis is 
being planned. 3D-Bioinfo will continuously seek to integrate 
biocomputational efforts with experimental studies in order 
to systematically generate, test and critically assess new 
hypotheses on the fundamental properties of highly active 
enzymes and binding proteins. This would very much increase 
our quantitative understanding and enhance the capabilities for 
the rapid generation of binders, inhibitors and biocatalysts for 
a range of applications in research, technology and medicine.
Interaction of 3D-Bioinfo with other research 
communities
Alignment with the ELIXIR platforms
All the above 3D-Bioinfo Activities will engage with the 
ELIXIR platforms as described below.
Interoperability platform – The outcomes of our projects must 
be easy to discover, to access and to integrate into users’ pipe-
lines. This necessitates the use of standardised file formats, 
metadata, vocabularies and identifiers. We plan to include our 
resources in FAIRshairing and Identifiers.org. For all Activities 
we will organise community workshops to develop data 
exchange and retrieval standards to improve compliance 
with FAIR principles. Participating teams will also adopt 
BioSchemas69, a European led initiative. For example, different 
community-wide standards for evaluating predicted models 
of proteins and protein complexes would be integrated to 
promote community-wide use. FAIR-ification of benchmark 
datasets will be undertaken. To implement the 3D-Beacons 
infrastructure, we will implement a common API specifica-
tion for macromolecular structure data from both experimen-
tally determined and predicted models. Where possible, the 
services and tools will also be linked via workflows using 
common workflow language to help with interoperable 
workflow software development.
Data platform – We will link key structural bioinformatics 
data resources to drive the use and re-use of data. For example, 
data from five UK based structure prediction resources have 
already been integrated via Genome3D, and ELIXIR imple-
mentation studies are already supporting further integration 
of the data in Genome3D with data from SWISS-MODEL, 
developed by the Swiss node. In addition, Activity I will be 
responsible for the integration of data on known and pre-
dicted functional sites, from a large number of participating 
European groups, in PDBe-KB. Information on the structural 
impacts of genetic variations predicted by multiple groups 
will also be integrated and novel visualization strategies for 
presenting this integrated data will be developed. These will 
need to clearly distinguish between experimentally known and 
predicted data. Activity II will be responsible for integrating 
various benchmark datasets on predicted protein complexes 
and assemblies, and on experimentally determined complexes 
annotated with data from other sources (in close coordination 
with Activity I). Activity III will also integrate benchmark data-
sets. For example, we will establish Open Access benchmarks 
sets under FAIR principles, for assessing structure-based drug 
design applications. This must be done in a robust, sustainable 
and scalable data ecosystem, allowing the use and re-use of 
the data, in line with the ELIXIR Data Platform goals.
Tools platform – The participating tools and resources will 
be registered in BioTools to make them discoverable and 
sustainable. Currently, there are several hundred tools relating 
to structural bioinformatics registered in BioTools covering 
a range of themes. Extending the repertoire of structural 
bioinformatics tools in BioTools will a) ensure reproducibility, 
b) allow scaling up by working in cloud environments, 
e.g. EOSC c) make tools widely available and sustainable for 
non-expert users. Containerization of these tools in BioContainers 
will support development of complex workflows. We will use 
the benchmarking infrastructure OpenEBench to assess tools 
and help methods development. For example, all tools related 
to Activity I will be registered in BioTools and the developers 
will have the opportunity to access expertise on containerization; 
for Activity II, these will incorporate exemplary datasets from 
CAMEO and CAPRI. Workflows for modeling protein con-
formational flexibility and for modelling protein assemblies 
in the context of Cryo-EM structure determination will be 
designed in collaboration with respectively, BioExcel and 
Instruct-ERIC. The development of improved tools for valida-
tion of nucleic acid models in Activity IV feeds directly into this 
platform and all new methods will be registered with BioTools.
Compute platform – The ELIXIR Authentication & Authori-
sation Infrastructure (ELIXIR-AAI) which connects to other 
European AAI initiatives like EGI-CheckIn, INSTRACT 
ARIA, will be adopted to support depositions. We will link with 
the compute platform activities to address scalability of the 
underlying infrastructure for data transfer as well as data 
access. For example, access to the ELIXIR compute infra-
structure and to the European Open Science Cloud resources 
(EOSC-Hub) will be explored, to enable large-scale assess-
ment of predicted models of protein assemblies in CAPRI 
prediction rounds, and to disseminate software tools and 
web-services. Similarly, groups providing large-scale protein 
structure predictions and variant impacts will seek to benefit 
from access to the ELIXIR compute infrastructure. We will 
adopt ELIXIR Authentication & Authorisation Infrastruc-
ture (ELIXIR-AAI) to support deposition of ligand-protein 
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complexes or benchmark results into our future infrastructure. 
We also need to provide an easy way to store and synchronise 
our datasets and users’ benchmarks results across ELIXIR 
and other e-Infrastructures.
Training platform – PDBe-KB and participating data resources 
will work to add training workflows to the TeSS portal. 
As mentioned already, ELIXIR-UK funding has already 
supported preliminary work on these workflows involving 
collaborations between multiple partners. Proteopedia, which is 
being developed in collaboration between the Israeli node and 
PDBe at the hub, will also be a valuable mechanism for train-
ing and outreach (see Figure 4). Connections with existing 
initiatives such as the BioExcel Knowledge Resource Center 
will be established. The BioExcel knowledge resource center is 
a repository for computational biomolecular training resources. 
The resources are primarily online based, such as tutorials, 
online courses and videos but also include face-to-face events.
With regards to protein ligand interactions, we will train 
researchers on the best way to retrieve and use our benchmark 
datasets, and promote the usage of preferred benchmark con-
ditions. The Molecular Modeling Group of the SIB Swiss 
Institute of Bioinformatics will enhance the Drug Design 
Workshop. This is a web-based educational tool70 to intro-
duce structure-based computer-aided drug design to the 
general public. This online workshop constitutes a helpful tool to 
introduce the concepts of structure-based drug design to young 
students (15−19 years old) and to the general public. It can also 
be used as an introductory tool for more advanced students. 
Several routes of enhancements will be followed, including 
a better visualization and analysis of the ligand-protein 
complex, or the selection of new protein targets.
Building on the experience of the CAPRI community in organ-
izing the well-attended EMBO courses on Integrative of 
Biomolecular Complexes (3 editions so far), Activity II will 
coordinate various training activities and workshops on 
teaching non-experts how to use protein structure and assem-
bly prediction tools and how to benchmark new prediction 
methods using various datasets assembled in Activity 
II. Training workflows will be derived and added to the TeSS 
Figure 4. The tRNA page from Proteopedia [http://proteopedia.org/w/TRNA]. tRNA plays a key role in translation, the process of synthesizing 
proteins from amino acids. The two arms of the “L” shaped molecule (cartoon) are formed by the stacking of the acceptor and TΨC-stem.
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portal. Activity II will also help coordinate training tasks related 
to protein structure prediction in the Meet-U initiative. This is 
an innovative pedagogical initiative created in 2016 that 
teaches MSc students by involving them in real world 
research projects, with results evaluated by experts in the 
field during a final scientific symposium. Meet-U is currently 
implemented as a collaborative course between three universi-
ties of Paris/France area: Sorbonne Université (SU/UPMC), 
Universités Paris-Sud/Paris-Saclay, and Université Paris-Diderot. 
It is proposed to implement an international version of Meet-U, 
involving universities linked to ELIXIR nodes across Europe.
There has also been some support from the ELIXIR UK 
node to develop training workflows in protein structure pre-
diction and variant impact analysis. This has enabled pilot 
work and the establishment of small-scale training workflows 
in the ELIXIR TESS registry. For all activities, we will organise 
training workshops for trainers and users, and add workflows 
to TeSS where appropriate.
Connection to other communities and European 
infrastructure initiatives
3D-Bioinfo community users: The 3D-Bioinfo community 
bridges several infrastructures and their providers as well as users, 
namely people and tools of structural biology (Instruct-ERIC, 
iNEXT), cheminformatics (OpenScreen), system biology 
(ISBE), molecular simulations (BioExcel) and the proposed 
community for intrinsically disordered proteins (IDP). In addi-
tion, the value of structural data in providing insights into the 
impacts of genetic variations has led to involvement of some 
of the 3D-BioInfo participating groups with the ELIXIR 
Rare Disease Community. Similarly, work in all Activities on 
structural impacts of residue mutations and other research 
fields of protein engineering and nucleic acid analogues 
would clearly enable links with the newly emerging ELIXIR 
Community on Synthetic Biology. The action plan of this com-
munity includes the development of new strains with designed 
metabolic pathways and expression systems. The synergy 
of the expertise in the 3D-Bioinfo and Synthetic Biology 
communities will therefore be very important to implement 
the new biotech applications that can be expected to be gener-
ated through the acquired knowledge and expertise generated 
by the 3D-Bioinfo ELIXIR community.
The tools and services offered by the proposed 3D-Bioinfo 
Community already have many millions of users per year and 
the new Activities, described above, will undoubtedly broaden 
this scope.
As regards potential overlap with Instruct-ERIC, the 3D- 
Bioinfo community develops tools that go beyond the scope 
of structural biology and are not covered by the Instruct-ERIC 
initiatives and efforts. We will work closely with Instruct-ERIC 
on common areas of interest (e.g. methods for validating 
experimental protein and nucleic acid structures) and seek 
support for joint implementations studies.
Connection with industry
Industry and SME involvement – As mentioned already, 
Activity III (linked to structure-based drug design) is of par-
ticular relevance for the pharmaceutical and biotechnology 
industries, particularly those using computer-aided structure- 
based drug design programs. Companies involved in the 
development of scientific software as well as novel bioactive 
compounds acknowledge the importance of developing 
benchmarking protocols, and participate in the D3R Grand 
Challenges by providing undisclosed data. Furthermore, 
as regards Activity I, PDBe-KB has interactions with 
OpenTargets platform and provides annotations to major data 
resources (UniProt, InterPro and Pfam). Development of data 
standards and distributable infrastructure would further improve 
accessibility of the added value annotation data for industry 
users where all four Activities will contribute. We also expect 
to build up links to the pharmaceutical Industry via the collabo-
rations with BioExcel, and Instruct-ERIC. Future 3D-Bioinfo 
Activities around protein and enzyme engineering are expected 
to provide strong links with the industry and it is anticipated 
that these links will very much strengthen the competitiveness 
of the developing European biotechnology SMEs.
Integration at a global level
Clearly the ontologies and data exchange formats established 
and endorsed through 3D-Bioinfo enabled collaborations will 
be valuable in a global context as well as across Europe. In 
fact many of the initiatives we will foster such as PDBe-KB, 
CAPRI and CAMEO already involve other international 
partners outside Europe. Furthermore, 3D-Bioinfo groups are 
involved in organising the international community-wide 
CASP benchmarking of protein structure prediction. We will 
support and where possible engage in initiatives for global 
health, for example the Global Alliance for Genomics and 
Health (GA4GH). We plan to present activities and output 
from 3D-Bioinfo in special sessions or technology tracks at 
the European ECCB and international ISMB conferences, the 
latter of which is held in Europe on alternate years. This will 
publicise our activities to the wider bioinformatics community, 
enable us to recruit additional European participants and promote 
links with other international initiatives.
Conclusions
This proposal capitalises on the extensive European struc-
tural bioinformatics expertise. It provides a discussion and 
action framework for joint development of current and future 
activities within the European structural bioinformatics 
community. 3D-Bioinfo will very much foster the interactions 
with experimental research groups to efficiently reach a better 
understanding of proteins and their functional properties at a 
quantitative level. 3D-Bioinfo will also foster focused outreach 
and training activities. The outlined aims of our planned 
Activities should facilitate valuable coordination for optimal 
use of resources and exploit ELIXIRs platforms to good 
purpose. As demonstrated in our background to this paper 
and the many tools/resources listed in the BioTools, Europe is 
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very strong in this area of research and the establishment of the 
3D-Bioinfo Community will assist in promoting research 
interactions, integration of data and tools and standardised prac-
tices, making it even stronger. Furthermore, the Community 
will facilitate the translation of structurally derived insights 
- in medicine (pharmaceuticals, diagnostics), agriculture, 
and sustainable production methods. Finally, 3D-Bioinfo 
will facilitate collaborations worldwide and promote 
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These are small typo or missing comas that are pretty harmless individually, but some can be misleading.
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